Multi-Specific Antibodies Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Multi-Specific Antibodies Market: Product Type (Bispecific, Tri specific), Indication (Oncology, Immunology), Clinical Phase and Commercial (Phase I, Phase II, Phase III, Marketed), and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

1. Executive Summary
2. Global Multi-Specific Antibodies Market Introduction
2.1. Global Multi-Specific Antibodies Market – Taxonomy
2.2. Global Multi-Specific Antibodies Market –Definitions
2.2.1. Product Type
2.2.2. Indication
2.2.3. Clinical Phase and Commercial
2.2.4. Region
3. Global Multi-Specific Antibodies Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Multi-Specific Antibodies Market Dynamic Factors – Impact Analysis
3.6. Impact of COVID 19 on The Market
3.7. Three Forecast Scenarios – Pessimistic, Conservative and Opportunistic
3.8. Mapping Market Players Activities
3.9. Recent Key Developments
3.10. Financial Status of the Market Players
3.11. Recent Acquisitions, Collaborations and Mergers
4. Global Multi-Specific Antibodies Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Multi-Specific Antibodies Market Forecast, By Product Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1. Bispecific
5.1.1. Blinatumomab
5.1.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. Emicizumab
5.1.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.1.3. Amivantamab-vmjw
5.1.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3.3. Market Opportunity Analysis
5.1.4. Faricimab-svoa
5.1.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.4.3. Market Opportunity Analysis
5.1.5. Mosunetuzumab
5.1.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.5.3. Market Opportunity Analysis
5.1.6. Catumaxomab
5.1.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.6.3. Market Opportunity Analysis
5.1.7. Teclistamab
5.1.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.7.3. Market Opportunity Analysis
5.2. Trispecific
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6. Global Multi-Specific Antibodies Market Forecast, By Indication, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1. Oncology
6.1.1. Diffuse Large B cell Lymphoma
6.1.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.1.3. Market Opportunity Analysis
6.1.2. Non-Hodgkin’s Lymphoma
6.1.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.2.3. Market Opportunity Analysis
6.1.3. Multiple Myeloma
6.1.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3.3. Market Opportunity Analysis
6.1.4. Non-Small Cell Lung Cancer
6.1.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.4.3. Market Opportunity Analysis
6.1.5. Gastric Cancer
6.1.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.5.3. Market Opportunity Analysis
6.1.6. Ovarian Cancer
6.1.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.6.3. Market Opportunity Analysis
6.1.7. Cervical
6.1.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.7.3. Market Opportunity Analysis
6.1.8. Gastroesophageal Cancer
6.1.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.8.3. Market Opportunity Analysis
6.1.9. Others
6.1.10. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.11. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.12. Market Opportunity Analysis
6.2. Immunology
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Multi-Specific Antibodies Market Forecast, By Clinical Phase and Commercial, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1. Phase I
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Phase II
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Phase III
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Marketed
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global Multi-Specific Antibodies Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1. North America
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Multi-Specific Antibodies Market – Opportunity Analysis Index, By Product Type, Indication, Clinical Phase and Commercial, and Region, 2022 – 2028
9. North America Multi-Specific Antibodies Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.1.1. Bispecific
9.1.1.1. Blinatumomab
9.1.1.2. Emicizumab
9.1.1.3. Amivantamab-vmjw
9.1.1.4. Faricimab-svoa
9.1.1.5. Mosunetuzumab
9.1.1.6. Catumaxomab
9.1.1.7. Teclistamab
9.1.2. Trispecific
9.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Oncology
9.2.1.1. Diffuse Large B cell Lymphoma
9.2.1.2. Non-Hodgkin’s Lymphoma
9.2.1.3. Multiple Myeloma
9.2.1.4. Non-Small Cell Lung Cancer
9.2.1.5. Gastric Cancer
9.2.1.6. Ovarian Cancer
9.2.1.7. Cervical
9.2.1.8. Gastroesophageal Cancer
9.2.1.9. Others
9.2.2. Immunology
9.2.3. Others
9.3. Clinical Phase and Commercial Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Phase I
9.3.2. Phase II
9.3.3. Phase III
9.3.4. Marketed
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Multi-Specific Antibodies Market – Opportunity Analysis Index, By Product Type, Indication, Clinical Phase and Commercial, and Country, 2022 – 2028
9.6. North America Multi-Specific Antibodies Market Dynamics – Trends
10. Europe Multi-Specific Antibodies Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
10.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.1.1. Bispecific
10.1.1.1. Blinatumomab
10.1.1.2. Emicizumab
10.1.1.3. Amivantamab-vmjw
10.1.1.4. Faricimab-svoa
10.1.1.5. Mosunetuzumab
10.1.1.6. Catumaxomab
10.1.1.7. Teclistamab
10.1.2. Trispecific
10.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Oncology
10.2.1.1. Diffuse Large B cell Lymphoma
10.2.1.2. Non-Hodgkin’s Lymphoma
10.2.1.3. Multiple Myeloma
10.2.1.4. Non-Small Cell Lung Cancer
10.2.1.5. Gastric Cancer
10.2.1.6. Ovarian Cancer
10.2.1.7. Cervical
10.2.1.8. Gastroesophageal Cancer
10.2.1.9. Others
10.2.2. Immunology
10.2.3. Others
10.3. Clinical Phase and Commercial Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Phase I
10.3.2. Phase II
10.3.3. Phase III
10.3.4. Marketed
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Multi-Specific Antibodies Market – Opportunity Analysis Index, By Product Type, Indication, Clinical Phase and Commercial, and Country, 2022 – 2028
10.6. Europe Multi-Specific Antibodies Market Dynamics – Trends
11. Asia-Pacific Multi-Specific Antibodies Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
11.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.1.1. Bispecific
11.1.1.1. Blinatumomab
11.1.1.2. Emicizumab
11.1.1.3. Amivantamab-vmjw
11.1.1.4. Faricimab-svoa
11.1.1.5. Mosunetuzumab
11.1.1.6. Catumaxomab
11.1.1.7. Teclistamab
11.1.2. Trispecific
11.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Oncology
11.2.1.1. Diffuse Large B cell Lymphoma
11.2.1.2. Non-Hodgkin’s Lymphoma
11.2.1.3. Multiple Myeloma
11.2.1.4. Non-Small Cell Lung Cancer
11.2.1.5. Gastric Cancer
11.2.1.6. Ovarian Cancer
11.2.1.7. Cervical
11.2.1.8. Gastroesophageal Cancer
11.2.1.9. Others
11.2.2. Immunology
11.2.3. Others
11.3. Clinical Phase and Commercial Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Phase I
11.3.2. Phase II
11.3.3. Phase III
11.3.4. Marketed
11.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Rest of Asia-Pacific
11.5. Asia-Pacific Multi-Specific Antibodies Market – Opportunity Analysis Index, By Product Type, Indication, Clinical Phase and Commercial, and Country, 2022 – 2028
11.6. Asia-Pacific Multi-Specific Antibodies Market Dynamics – Trends
12. Latin America Multi-Specific Antibodies Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
12.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.1.1. Bispecific
12.1.1.1. Blinatumomab
12.1.1.2. Emicizumab
12.1.1.3. Amivantamab-vmjw
12.1.1.4. Faricimab-svoa
12.1.1.5. Mosunetuzumab
12.1.1.6. Catumaxomab
12.1.1.7. Teclistamab
12.1.2. Trispecific
12.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Oncology
12.2.1.1. Diffuse Large B cell Lymphoma
12.2.1.2. Non-Hodgkin’s Lymphoma
12.2.1.3. Multiple Myeloma
12.2.1.4. Non-Small Cell Lung Cancer
12.2.1.5. Gastric Cancer
12.2.1.6. Ovarian Cancer
12.2.1.7. Cervical
12.2.1.8. Gastroesophageal Cancer
12.2.1.9. Others
12.2.2. Immunology
12.2.3. Others
12.3. Clinical Phase and Commercial Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Phase I
12.3.2. Phase II
12.3.3. Phase III
12.3.4. Marketed
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Argentina
12.4.3. Rest of Latin America
12.5. Latin America Multi-Specific Antibodies Market – Opportunity Analysis Index, By Product Type, Indication, Clinical Phase and Commercial, and Country, 2022 – 2028
12.6. Latin America Multi-Specific Antibodies Market Dynamics – Trends
13. Middle East and Africa Multi-Specific Antibodies Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
13.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.1.1. Bispecific
13.1.1.1. Blinatumomab
13.1.1.2. Emicizumab
13.1.1.3. Amivantamab-vmjw
13.1.1.4. Faricimab-svoa
13.1.1.5. Mosunetuzumab
13.1.1.6. Catumaxomab
13.1.1.7. Teclistamab
13.1.2. Trispecific
13.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Oncology
13.2.1.1. Diffuse Large B cell Lymphoma
13.2.1.2. Non-Hodgkin’s Lymphoma
13.2.1.3. Multiple Myeloma
13.2.1.4. Non-Small Cell Lung Cancer
13.2.1.5. Gastric Cancer
13.2.1.6. Ovarian Cancer
13.2.1.7. Cervical
13.2.1.8. Gastroesophageal Cancer
13.2.1.9. Others
13.2.2. Immunology
13.2.3. Others
13.3. Clinical Phase and Commercial Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Phase I
13.3.2. Phase II
13.3.3. Phase III
13.3.4. Marketed
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Saudi Arabia
13.4.2. GCC Countries
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Multi-Specific Antibodies Market – Opportunity Analysis Index, By Product Type, Indication, Clinical Phase and Commercial, and Country, 2022 – 2028
13.6. MEA Multi-Specific Antibodies Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product Type Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Zymeworks
14.2.2. Merck
14.2.3. Adimab, LLC
14.2.4. Ichnos
14.2.5. F. Hoffmann-La Roche Ltd
14.2.6. Pfizer
14.2.7. Amgen
14.2.8. Sanofi
14.2.9. Eli Lilly
14.2.10. Merus NV
14.2.11. Gilead
14.2.12. Fresenius Biotech
14.2.13. Trion Pharma
15. Research Methodology
 16. Key Assumptions and Acronyms

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Company Profile

 

  • Zymeworks
  • Merck
  • Adimab, LLC
  • Ichnos
  • Pfizer
  • Amgen
  • Sanofi
  • Eli Lilly
  • Merus NV
  •  Gilead
  • Fresenius Biotech
  • Trion Pharma
  • Hoffmann-La Roche Ltd

Description

1. Executive Summary
2. Global Multi-Specific Antibodies Market Introduction
2.1. Global Multi-Specific Antibodies Market – Taxonomy
2.2. Global Multi-Specific Antibodies Market –Definitions
2.2.1. Product Type
2.2.2. Indication
2.2.3. Clinical Phase and Commercial
2.2.4. Region
3. Global Multi-Specific Antibodies Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Multi-Specific Antibodies Market Dynamic Factors – Impact Analysis
3.6. Impact of COVID 19 on The Market
3.7. Three Forecast Scenarios – Pessimistic, Conservative and Opportunistic
3.8. Mapping Market Players Activities
3.9. Recent Key Developments
3.10. Financial Status of the Market Players
3.11. Recent Acquisitions, Collaborations and Mergers
4. Global Multi-Specific Antibodies Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Multi-Specific Antibodies Market Forecast, By Product Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1. Bispecific
5.1.1. Blinatumomab
5.1.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. Emicizumab
5.1.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.1.3. Amivantamab-vmjw
5.1.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3.3. Market Opportunity Analysis
5.1.4. Faricimab-svoa
5.1.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.4.3. Market Opportunity Analysis
5.1.5. Mosunetuzumab
5.1.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.5.3. Market Opportunity Analysis
5.1.6. Catumaxomab
5.1.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.6.3. Market Opportunity Analysis
5.1.7. Teclistamab
5.1.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.7.3. Market Opportunity Analysis
5.2. Trispecific
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6. Global Multi-Specific Antibodies Market Forecast, By Indication, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1. Oncology
6.1.1. Diffuse Large B cell Lymphoma
6.1.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.1.3. Market Opportunity Analysis
6.1.2. Non-Hodgkin’s Lymphoma
6.1.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.2.3. Market Opportunity Analysis
6.1.3. Multiple Myeloma
6.1.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3.3. Market Opportunity Analysis
6.1.4. Non-Small Cell Lung Cancer
6.1.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.4.3. Market Opportunity Analysis
6.1.5. Gastric Cancer
6.1.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.5.3. Market Opportunity Analysis
6.1.6. Ovarian Cancer
6.1.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.6.3. Market Opportunity Analysis
6.1.7. Cervical
6.1.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.7.3. Market Opportunity Analysis
6.1.8. Gastroesophageal Cancer
6.1.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.8.3. Market Opportunity Analysis
6.1.9. Others
6.1.10. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.11. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.12. Market Opportunity Analysis
6.2. Immunology
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Multi-Specific Antibodies Market Forecast, By Clinical Phase and Commercial, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1. Phase I
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Phase II
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Phase III
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Marketed
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global Multi-Specific Antibodies Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1. North America
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Multi-Specific Antibodies Market – Opportunity Analysis Index, By Product Type, Indication, Clinical Phase and Commercial, and Region, 2022 – 2028
9. North America Multi-Specific Antibodies Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.1.1. Bispecific
9.1.1.1. Blinatumomab
9.1.1.2. Emicizumab
9.1.1.3. Amivantamab-vmjw
9.1.1.4. Faricimab-svoa
9.1.1.5. Mosunetuzumab
9.1.1.6. Catumaxomab
9.1.1.7. Teclistamab
9.1.2. Trispecific
9.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Oncology
9.2.1.1. Diffuse Large B cell Lymphoma
9.2.1.2. Non-Hodgkin’s Lymphoma
9.2.1.3. Multiple Myeloma
9.2.1.4. Non-Small Cell Lung Cancer
9.2.1.5. Gastric Cancer
9.2.1.6. Ovarian Cancer
9.2.1.7. Cervical
9.2.1.8. Gastroesophageal Cancer
9.2.1.9. Others
9.2.2. Immunology
9.2.3. Others
9.3. Clinical Phase and Commercial Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Phase I
9.3.2. Phase II
9.3.3. Phase III
9.3.4. Marketed
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Multi-Specific Antibodies Market – Opportunity Analysis Index, By Product Type, Indication, Clinical Phase and Commercial, and Country, 2022 – 2028
9.6. North America Multi-Specific Antibodies Market Dynamics – Trends
10. Europe Multi-Specific Antibodies Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
10.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.1.1. Bispecific
10.1.1.1. Blinatumomab
10.1.1.2. Emicizumab
10.1.1.3. Amivantamab-vmjw
10.1.1.4. Faricimab-svoa
10.1.1.5. Mosunetuzumab
10.1.1.6. Catumaxomab
10.1.1.7. Teclistamab
10.1.2. Trispecific
10.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Oncology
10.2.1.1. Diffuse Large B cell Lymphoma
10.2.1.2. Non-Hodgkin’s Lymphoma
10.2.1.3. Multiple Myeloma
10.2.1.4. Non-Small Cell Lung Cancer
10.2.1.5. Gastric Cancer
10.2.1.6. Ovarian Cancer
10.2.1.7. Cervical
10.2.1.8. Gastroesophageal Cancer
10.2.1.9. Others
10.2.2. Immunology
10.2.3. Others
10.3. Clinical Phase and Commercial Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Phase I
10.3.2. Phase II
10.3.3. Phase III
10.3.4. Marketed
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Multi-Specific Antibodies Market – Opportunity Analysis Index, By Product Type, Indication, Clinical Phase and Commercial, and Country, 2022 – 2028
10.6. Europe Multi-Specific Antibodies Market Dynamics – Trends
11. Asia-Pacific Multi-Specific Antibodies Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
11.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.1.1. Bispecific
11.1.1.1. Blinatumomab
11.1.1.2. Emicizumab
11.1.1.3. Amivantamab-vmjw
11.1.1.4. Faricimab-svoa
11.1.1.5. Mosunetuzumab
11.1.1.6. Catumaxomab
11.1.1.7. Teclistamab
11.1.2. Trispecific
11.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Oncology
11.2.1.1. Diffuse Large B cell Lymphoma
11.2.1.2. Non-Hodgkin’s Lymphoma
11.2.1.3. Multiple Myeloma
11.2.1.4. Non-Small Cell Lung Cancer
11.2.1.5. Gastric Cancer
11.2.1.6. Ovarian Cancer
11.2.1.7. Cervical
11.2.1.8. Gastroesophageal Cancer
11.2.1.9. Others
11.2.2. Immunology
11.2.3. Others
11.3. Clinical Phase and Commercial Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Phase I
11.3.2. Phase II
11.3.3. Phase III
11.3.4. Marketed
11.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Rest of Asia-Pacific
11.5. Asia-Pacific Multi-Specific Antibodies Market – Opportunity Analysis Index, By Product Type, Indication, Clinical Phase and Commercial, and Country, 2022 – 2028
11.6. Asia-Pacific Multi-Specific Antibodies Market Dynamics – Trends
12. Latin America Multi-Specific Antibodies Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
12.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.1.1. Bispecific
12.1.1.1. Blinatumomab
12.1.1.2. Emicizumab
12.1.1.3. Amivantamab-vmjw
12.1.1.4. Faricimab-svoa
12.1.1.5. Mosunetuzumab
12.1.1.6. Catumaxomab
12.1.1.7. Teclistamab
12.1.2. Trispecific
12.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Oncology
12.2.1.1. Diffuse Large B cell Lymphoma
12.2.1.2. Non-Hodgkin’s Lymphoma
12.2.1.3. Multiple Myeloma
12.2.1.4. Non-Small Cell Lung Cancer
12.2.1.5. Gastric Cancer
12.2.1.6. Ovarian Cancer
12.2.1.7. Cervical
12.2.1.8. Gastroesophageal Cancer
12.2.1.9. Others
12.2.2. Immunology
12.2.3. Others
12.3. Clinical Phase and Commercial Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Phase I
12.3.2. Phase II
12.3.3. Phase III
12.3.4. Marketed
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Argentina
12.4.3. Rest of Latin America
12.5. Latin America Multi-Specific Antibodies Market – Opportunity Analysis Index, By Product Type, Indication, Clinical Phase and Commercial, and Country, 2022 – 2028
12.6. Latin America Multi-Specific Antibodies Market Dynamics – Trends
13. Middle East and Africa Multi-Specific Antibodies Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
13.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.1.1. Bispecific
13.1.1.1. Blinatumomab
13.1.1.2. Emicizumab
13.1.1.3. Amivantamab-vmjw
13.1.1.4. Faricimab-svoa
13.1.1.5. Mosunetuzumab
13.1.1.6. Catumaxomab
13.1.1.7. Teclistamab
13.1.2. Trispecific
13.2. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Oncology
13.2.1.1. Diffuse Large B cell Lymphoma
13.2.1.2. Non-Hodgkin’s Lymphoma
13.2.1.3. Multiple Myeloma
13.2.1.4. Non-Small Cell Lung Cancer
13.2.1.5. Gastric Cancer
13.2.1.6. Ovarian Cancer
13.2.1.7. Cervical
13.2.1.8. Gastroesophageal Cancer
13.2.1.9. Others
13.2.2. Immunology
13.2.3. Others
13.3. Clinical Phase and Commercial Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Phase I
13.3.2. Phase II
13.3.3. Phase III
13.3.4. Marketed
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Saudi Arabia
13.4.2. GCC Countries
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Multi-Specific Antibodies Market – Opportunity Analysis Index, By Product Type, Indication, Clinical Phase and Commercial, and Country, 2022 – 2028
13.6. MEA Multi-Specific Antibodies Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product Type Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Zymeworks
14.2.2. Merck
14.2.3. Adimab, LLC
14.2.4. Ichnos
14.2.5. F. Hoffmann-La Roche Ltd
14.2.6. Pfizer
14.2.7. Amgen
14.2.8. Sanofi
14.2.9. Eli Lilly
14.2.10. Merus NV
14.2.11. Gilead
14.2.12. Fresenius Biotech
14.2.13. Trion Pharma
15. Research Methodology
 16. Key Assumptions and Acronyms

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX